Cheng Sohanya Roshan (CIK 1865796) reported 10 SEC Form 4 insider transactions across 1 companies over the past 18 months (most recent 2026-05-15). Recent activity: Buy KPTI (947 shares), Sell KPTI (324 shares), Sell KPTI (4,604 shares), Buy KPTI (32,415 shares), Buy KPTI (43,650 shares). Source: SEC Form 4.
| Date | Company | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-15 | Karyopharm Therapeutics Inc. (KPTI) | EVP & Chief Commercial Officer | Buy | 947 | $0 |
| 2026-05-15 | Karyopharm Therapeutics Inc. (KPTI) | EVP & Chief Commercial Officer | Sell | 324 | $3,078 |
| 2026-03-03 | Karyopharm Therapeutics Inc. (KPTI) | EVP & Chief Commercial Officer | Sell | 4,604 | $43,324 |
| 2026-02-03 | Karyopharm Therapeutics Inc. (KPTI) | EVP & Chief Commercial Officer | Buy | 32,415 | $0 |
| 2025-10-16 | Karyopharm Therapeutics Inc. (KPTI) | EVP & Chief Commercial Officer | Buy | 43,650 | $0 |
| 2025-09-16 | Karyopharm Therapeutics Inc. (KPTI) | EVP & Chief Commercial Officer | Buy | 945 | $0 |
| 2025-09-16 | Karyopharm Therapeutics Inc. (KPTI) | EVP & Chief Commercial Officer | Sell | 325 | $2,090 |
| 2025-03-06 | Karyopharm Therapeutics Inc. (KPTI) | EVP & Chief Commercial Officer | Sell | 3,445 | $21,669 |
| 2025-03-04 | Karyopharm Therapeutics Inc. (KPTI) | EVP & Chief Commercial Officer | Buy | 5,416 | $0 |
| 2025-03-04 | Karyopharm Therapeutics Inc. (KPTI) | EVP & Chief Commercial Officer | Buy | 4,583 | $0 |
Source: SEC Form 4 filings · as of 2026-05-15